Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)

Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1) is a phase 2, interventional study registered as NCT06907342 by St. Olavs Hospital, with a registry enrolment figure of 148 participants, started 2025-05-23 and due to reach its primary completion in 2027-12. Interventions recorded: FOLFOX or FOLFIRI. Conditions listed: Tumor, Colorectal; Organoids; Tumoroid; Metastatic Colorectal Cancer; Core Needle Biopsy; First-line Treatment. Primary outcome: Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus irinotecan-based chemotherapy regimens for patients with metastatic colorectal cancer.; Test the feasibility of using a functional precision medicine platform to select oxaliplatin-based versus . Colorectal eligibility wording from the registry: "Histologically confirmed pMMR/MSS adenocarcinoma originating from the colon or rectum". Sites: Norway. No results are recorded here; the registry entry is the source.